Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2No longer available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Lymphoid 3

Conditions

Leukemia, Myeloid, Acute 35Myelodysplastic Syndromes 7Leukemia 5Mastocytosis, Systemic 4Congenital Abnormalities 4Leukemia, Mast-Cell 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm, Residual 2Aggression 2Recurrence 1Rectal Neoplasms 1Mastocytosis 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia, Basophilic, Acute 1GATA2 Deficiency 1Blast Crisis 1

Interventions

fludarabine phosphate 6Whole-Body Irradiation 5Therapeutics 5Mycophenolic Acid 5Cyclosporine 5Psychiatric Rehabilitation 4Peripheral Blood Stem Cell Transplantation 4midostaurin 3avapritinib 2Sunitinib 2Pentetic Acid 2Methotrexate 2Early Intervention, Educational 2Darbepoetin alfa 2Busulfan 2thymoglobulin 1ripretinib 1liposomal doxorubicin 1ibrutinib 1hydrocortisone valerate 1fludarabine 1ferrous sulfate 1ferric gluconate 1ethanolamine oleate 1denileukin diftitox 1Valganciclovir 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Thiotepa 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Mast-Cell × midostaurin × Clear all
NCT05219266 2024-06-28

Managed Access Programs for PKC412, Midostaurin

Novartis

No longer available
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT00782067 2018-11-15

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Novartis

Phase 2 Completed
116 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT00233454 2018-09-20

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

Stanford University

Phase 2 Completed
26 enrolled 12 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡